Pomalidomide-PEG2-butyl iodide is a specialty chemical intermediate designed for use in targeted cancer therapies. This compound conjugates pomalidomide, an immunomodulatory agent primarily used in treating multiple myeloma, with a PEG2 (polyethylene glycol) spacer and a butyl iodide linker. It enhances drug delivery systems by improving the solubility, bioavailability, and stability of small molecules. The PEG component reduces immunogenicity and extends circulation time in the body, making it essential for formulating efficient therapeutic agents. Commonly employed in research to optimize pharmacokinetics of drug candidates for multiple myeloma and other cancers, it plays a key role in synthesizing antibody-drug conjugates (ADCs), enabling precise targeting of cancer cells while sparing healthy tissues.